吉非替尼与吉非替尼加培美曲塞和卡铂化疗治疗表皮生长因子受体变异型肺癌--随机临床试验的长期结果

IF 22.5 1区医学 Q1 ONCOLOGY JAMA Oncology Pub Date : 2024-04-25 DOI:10.1001/jamaoncol.2024.0584

Vanita Noronha, Vijay Patil, Nandini Menon, Minit Shah, Anuradha Chougule, Zoya Peelay, Kumar Prabhash

引用次数: 0

摘要

这项随机临床试验探讨了在吉非替尼基础上加用培美曲塞和卡铂化疗是否能提高表皮生长因子受体（EGFR）变异型非小细胞肺癌患者的生存率。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

Gefitinib vs Gefitinib Plus Pemetrexed and Carboplatin Chemotherapy in EGFR-Variant Lung Cancer—Long-Term Results of a Randomized Clinical Trial

This randomized clinical trial examines whether adding chemotherapy with pemetrexed and carboplatin to gefitinib improves survival among patients with epidermal growth factor receptor (EGFR)–variant non–small cell lung cancer.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

JAMA Oncology Medicine-Oncology

自引率

1.80%

发文量

423

期刊介绍： JAMA Oncology is an international peer-reviewed journal that serves as the leading publication for scientists, clinicians, and trainees working in the field of oncology. It is part of the JAMA Network, a collection of peer-reviewed medical and specialty publications.